JP2019182869A5 - - Google Patents

Download PDF

Info

Publication number
JP2019182869A5
JP2019182869A5 JP2019104161A JP2019104161A JP2019182869A5 JP 2019182869 A5 JP2019182869 A5 JP 2019182869A5 JP 2019104161 A JP2019104161 A JP 2019104161A JP 2019104161 A JP2019104161 A JP 2019104161A JP 2019182869 A5 JP2019182869 A5 JP 2019182869A5
Authority
JP
Japan
Prior art keywords
hydroxy
pyrrolidin
propan
dioxin
dihydrobenzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019104161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019182869A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019182869A publication Critical patent/JP2019182869A/ja
Publication of JP2019182869A5 publication Critical patent/JP2019182869A5/ja
Pending legal-status Critical Current

Links

JP2019104161A 2013-09-20 2019-06-04 疾患治療用のグルコシルセラミドシンターゼ阻害剤 Pending JP2019182869A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361880752P 2013-09-20 2013-09-20
US61/880,752 2013-09-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016515409A Division JP6537500B2 (ja) 2013-09-20 2014-09-19 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Publications (2)

Publication Number Publication Date
JP2019182869A JP2019182869A (ja) 2019-10-24
JP2019182869A5 true JP2019182869A5 (https=) 2020-01-16

Family

ID=51794951

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016515409A Active JP6537500B2 (ja) 2013-09-20 2014-09-19 疾患治療用のグルコシルセラミドシンターゼ阻害剤
JP2019104161A Pending JP2019182869A (ja) 2013-09-20 2019-06-04 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016515409A Active JP6537500B2 (ja) 2013-09-20 2014-09-19 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Country Status (10)

Country Link
US (2) US10227323B2 (https=)
EP (2) EP3046920B1 (https=)
JP (2) JP6537500B2 (https=)
CN (2) CN105745206B (https=)
AU (2) AU2014321397C1 (https=)
CA (1) CA2924545C (https=)
IL (2) IL244628B (https=)
MX (1) MX374452B (https=)
TW (2) TW201945337A (https=)
WO (1) WO2015042397A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105745206B (zh) 2013-09-20 2019-08-13 生物马林药物股份有限公司 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂
US11744396B1 (en) * 2015-11-10 2023-09-05 Caffeine Innovations, LLC System, method, and device for agitating coffee grounds
CN105541819B (zh) * 2016-02-04 2018-09-14 浙江永宁药业股份有限公司 一种依匹唑派的制备方法及其中间体和中间体的制备方法
CN107216238A (zh) * 2016-03-21 2017-09-29 湖南师范大学 醇镁法制备4-甲基儿茶酚
JP6633814B2 (ja) * 2016-09-02 2020-01-22 アイジーエム グループ ビー.ヴィ. 光開始剤としての多環式グリオキシレート
WO2018118838A1 (en) * 2016-12-20 2018-06-28 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
CN110506038B (zh) 2017-03-28 2023-11-24 巴斯夫欧洲公司 杀害虫化合物
CA3086083A1 (en) 2017-12-21 2019-06-27 Basf Se Pesticidal compounds
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
CN111393405B (zh) 2019-01-02 2022-11-25 中国科学院上海药物研究所 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用
CN114340740A (zh) * 2019-07-01 2022-04-12 库拉森疗法公司 β肾上腺素能激动剂及其使用方法
EP4005638A4 (en) * 2019-07-29 2023-07-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
WO2021081141A1 (en) * 2019-10-23 2021-04-29 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
CN114746422B (zh) * 2019-11-15 2024-03-12 柳韩洋行 具有1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐以及包含它们的药物组合物
PL4041733T3 (pl) * 2019-11-15 2024-09-23 Yuhan Corporation Pochodne mające ugrupowanie 2,3-dihydro-1h-indenu lub 2,3-dihydrobenzofuranu lub ich farmaceutycznie dopuszczalne sole oraz kompozycje farmaceutyczne je zawierające
JP7725076B2 (ja) * 2020-04-28 2025-08-19 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン グルコシルセラミド合成酵素のピリジン阻害剤及びそれらを使用する治療方法
CN114621140B (zh) * 2020-12-10 2023-08-11 中国科学院上海药物研究所 芳基二氟乙酰胺化合物及其制备方法和用途
CN112457277B (zh) * 2020-12-16 2022-06-28 西安国康瑞金制药有限公司 一种他氟前列腺素的制备方法
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN113912544B (zh) * 2021-11-29 2023-03-17 沧州普瑞东方科技有限公司 一种5-溴-1-甲基吲唑的制备方法
AU2023325650A1 (en) * 2022-08-18 2025-02-27 Acelink Therapeutics, Inc. Crystalline forms of a glucosylceramide synthase inhibitor and uses thereof
CN115433157B (zh) * 2022-11-09 2023-02-07 苏州凯瑞医药科技有限公司 一种依利格鲁司特中间体的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756528A (en) 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
DK1176956T3 (da) 1999-05-07 2008-05-26 Encysive Pharmaceuticals Inc Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer
US6407064B2 (en) 1999-12-06 2002-06-18 Seikagaku Corporation Aminoalcohol derivative and medicament comprising the same
WO2002080920A1 (en) 2001-04-06 2002-10-17 Axys Pharmaceuticals, Inc. Arylacetamido-ketobenzoxazole as cysteine protease inhibitors
CA2453978C (en) 2001-07-16 2011-10-11 Genzyme Corporation Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
WO2003045928A1 (en) 2001-11-26 2003-06-05 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
AU2002367266A1 (en) 2001-12-28 2003-07-24 Sumitomo Pharmaceuticals Company, Limited Disease markers for renal diseaes and utilization thereof
WO2004080960A2 (en) 2003-03-06 2004-09-23 Neose Technologies Inc. Methods and compositions for the enzymatic synthesis of gangliosides
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
BR122020017756B1 (pt) * 2004-08-26 2022-02-15 Pfizer Inc Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
ES2380904T3 (es) 2005-01-26 2012-05-21 Allergan, Inc. Composiciones farmacéuticas que tienen un efecto analgésico y contienen 1-bencil-1-hidroxi-2,3-diamino-propil aminas, amidas del ácido 3-bencil-3-hidroxi-2-amino propiónico o compuestos relacionados
PL2032134T3 (pl) 2006-05-09 2015-11-30 Genzyme Corp Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów
WO2008011483A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
WO2008011487A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
WO2008109286A1 (en) 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds
EP2594562B1 (en) * 2007-05-31 2016-07-20 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
ES2660690T3 (es) 2007-10-05 2018-03-23 Genzyme Corporation Método para tratar poliquistosis renales con derivados de ceramida
KR101270122B1 (ko) 2007-11-01 2013-05-31 어큐셀라 인코포레이티드 안과 질환 및 장애를 치료하기 위한 아민 유도체 화합물
WO2009099736A2 (en) * 2008-02-06 2009-08-13 Lead Therapeutics, Inc. Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp)
WO2009117150A2 (en) 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
GB0817576D0 (en) 2008-09-25 2008-11-05 Lectus Therapeutics Ltd Calcium ion channel modulators & uses thereof
EP3078373A1 (en) 2008-10-03 2016-10-12 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitor
WO2011066352A1 (en) * 2009-11-27 2011-06-03 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase
US20110144081A1 (en) * 2009-12-15 2011-06-16 Henner Knust Pyrrolidine derivatives
WO2013059119A1 (en) * 2011-10-17 2013-04-25 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
EP2968268B1 (en) * 2013-03-15 2020-07-29 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
CN105745206B (zh) * 2013-09-20 2019-08-13 生物马林药物股份有限公司 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂

Similar Documents

Publication Publication Date Title
JP2019182869A5 (https=)
JP2016534023A5 (https=)
TWI567067B (zh) TrK抑制化合物
RU2586974C2 (ru) Ингибиторы катехол-о-метилтрансферазы и их применение при лечении психотических расстройств
US7074801B1 (en) Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
US8492582B2 (en) N-acyl anthranilic acid derivative or salt thereof
JP2021169499A (ja) ヒト血漿カリクレイン阻害剤
US20210338653A1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
KR20200136425A (ko) 옥사진 모노아실글리세롤 리파아제(magl) 억제제
BG108013A (bg) Заместени аминопроизводни и методи за използването им
JP2021533093A (ja) モノアシルグリセロールリパーゼ阻害剤としての新規複素環化合物
JP7034512B2 (ja) キナーゼ阻害剤としてのヘテロアリール化合物
AU2006239418A1 (en) Novel oxadiazole derivatives and their medical use
EP3083611B1 (en) Oxindole derivatives, preparation thereof and therapeutic use in the treatment of ampk-related diseases
KR20170094263A (ko) Nadph 옥시다제 억제제인 아미도 티아디아졸 유도체
JP7744350B2 (ja) 置換ピラゾロ-ピリミジンおよびその使用
MX2014013011A (es) Compuesto heterociclico nitrogenado.
JP2011530483A (ja) アミド化合物
KR20050004214A (ko) 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
JP2019163256A (ja) イミダゾピリダジン化合物
CN115989228A (zh) 杂环化合物
KR20140041609A (ko) 선택적 프로테인 키나제 저해제로서 옥사졸 및 티아졸 유도체
US20240299385A1 (en) 3-pyrrolylsulfonamide compounds as gpr17 antagonists
US11731943B2 (en) Therapeutic compounds, compositions and methods of use thereof
WO2015170775A1 (ja) 置換アゾール化合物及び糖尿病治療薬